Bleeding Risk With Antiplatelets and Bruton's Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bleeding Risk With Antiplatelets and Bruton's Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention

Published:2023-05 Issue:3 Volume:2 Page:100608
ISSN:2772-9303
Container-title:Journal of the Society for Cardiovascular Angiography & Interventions
language:en
Short-container-title:Journal of the Society for Cardiovascular Angiography & Interventions

Author:

Mendez-Ruiz Alan,Lossos Izidore S.^ORCID,Cohen Mauricio G.^ORCID

Publisher

Elsevier BV

Reference29 articles.

1. Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis;Brem;Blood Adv,2022

2. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

3. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib;Lipsky;Haematologica,2015

4. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions;Series;Haematologica,2019

5. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies;Shatzel;J Thromb Haemost,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management der kardiovaskulären Medikation während der CLL-Therapie;InFo Hämatologie + Onkologie;2024-07

2. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors;Current Cardiology Reports;2023-07-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP